Literature DB >> 7884650

Prediction of brain delivery of ofloxacin, a new quinolone, in the human from animal data.

J Kawakami1, K Yamamoto, Y Sawada, T Iga.   

Abstract

We attempted to predict the delivery of ofloxacin (OFLX), a new quinolone antibacterial agent (NQ), into cerebrospinal fluid (CSF) in the human based on the physiological properties and pharmacokinetic parameters of NQs in various animals. Physiological properties for evaluation of drug delivery into CSF such as volume and the bulk flow rate of CSF and weight of choroid plexus, were compared among the rat, rabbit, cat, dog, and human. Statistically significant correlations with power values of 0.82-0.89 in the linear regression were observed on log-log plots between brain weight and those properties of each species. Delivery of OFLX into CSF from blood was analyzed by "diffusion and flow model" with unidirectional efflux process from CSF to blood. The blood-CSF diffusion clearance and the efflux clearance of OFLX in the human were extrapolated from animal data based on the allometric correlations between brain weight and these parameters in the rat, rabbit, and dog. The apparent volume of distribution and the total body clearance of NQs in the human could also be predicted from animal data based on the classical Adolph-Dedrick approach. To simulate the CSF concentration-time profile of OFLX in the human by using these predicted parameters, it was necessary to consider both the lumbar CSF compartment and the ventricular CSF compartment. Both plasma and CSF concentration-time profiles of OFLX predicted from only animal experimental data were in good agreement with those observed clinically.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7884650     DOI: 10.1007/bf02353329

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  51 in total

Review 1.  Tissue penetration of the new quinolones in humans.

Authors:  D N Gerding; J A Hitt
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

2.  Leucine transport from the ventricles and the cranial subarachnoid space in the cat.

Authors:  A V Lorenzo; S R Snodgrass
Journal:  J Neurochem       Date:  1972-05       Impact factor: 5.372

3.  Potassium exchange between cerebrospinal fluid, plasma, and brain.

Authors:  H Cserr
Journal:  Am J Physiol       Date:  1965-12

4.  Prediction of the volumes of distribution of basic drugs in humans based on data from animals.

Authors:  Y Sawada; M Hanano; Y Sugiyama; H Harashima; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1984-12

5.  Arterial drug infusion with extracorporeal removal. I. Theoretic basis with particular reference to the brain.

Authors:  R L Dedrick; E H Oldfield; J M Collins
Journal:  Cancer Treat Rep       Date:  1984-02

6.  Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration.

Authors:  R G Blasberg; C S Patlak; W R Shapiro
Journal:  Cancer Treat Rep       Date:  1977-07

Review 7.  Quinolone therapy for infections of the central nervous system.

Authors:  W M Scheld
Journal:  Rev Infect Dis       Date:  1989 Jul-Aug

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

Review 9.  Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.

Authors:  Y Sawada; M Hanano; Y Sugiyama; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1985-10

Review 10.  Unique aspects of quinolone pharmacokinetics.

Authors:  H Lode; G Höffken; K Borner; P Koeppe
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more
  11 in total

1.  Allometric scaling of xenobiotic clearance: uncertainty versus universality.

Authors:  T M Hu; W L Hayton
Journal:  AAPS PharmSci       Date:  2001

Review 2.  Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

Authors:  Elizabeth C M de Lange; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

4.  Prediction of drug clearance in humans from laboratory animals based on body surface area.

Authors:  X D Liu; J Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

5.  Nanotechnology-mediated crossing of two impermeable membranes to modulate the stars of the neurovascular unit for neuroprotection.

Authors:  Bapurao Surnar; Uttara Basu; Bhabatosh Banik; Anis Ahmad; Brian Marples; Nagesh Kolishetti; Shanta Dhar
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-10       Impact factor: 11.205

Review 6.  Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Authors:  Yumi Yamamoto; Meindert Danhof; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-03-09       Impact factor: 4.009

7.  Tolerance and pharmacokinetics of a ciprofloxacin-coated sinus stent in a preclinical model.

Authors:  Do-Yeon Cho; Kyle Hoffman; Daniel Skinner; Calvin Mackey; Dong Jin Lim; Grant C Alexander; Chae Yun Bae; Dong Keun Han; Ho-Wook Jun; Bradford A Woodworth
Journal:  Int Forum Allergy Rhinol       Date:  2016-12-19       Impact factor: 3.858

8.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

9.  Modeling of transfer kinetics at the serum-cerebrospinal fluid barrier in rabbits with experimental meningitis: application to grepafloxacin.

Authors:  Marc Pfister; Liping Zhang; Margareta Hammarlund-Udenaes; Lewis B Sheiner; Cynthia M Gerber; Martin G Täuber; Philippe Cottagnoud
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

10.  Pharmacokinetic Modeling of the Impact of P-glycoprotein on Ondansetron Disposition in the Central Nervous System.

Authors:  Manting Chiang; Hyun-Moon Back; Jong Bong Lee; Sarah Oh; Tiffany Guo; Simone Girgis; Celine Park; Simon Haroutounian; Leonid Kagan
Journal:  Pharm Res       Date:  2020-09-28       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.